Mga Batayang Estadistika
| LEI | 549300JV2CYDOME5OO17 |
| CIK | 1274737 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Exagen Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 29, 2025 |
Exagen Inc. Reports Strong Q2 2025 Results Exagen Inc. Reports Strong Q2 2025 Results July 29, 2025 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (Unaudited, in thousands, except ASP data) Revenue $ 17,202 $ 15,064 $ |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specif |
|
| July 17, 2025 |
Exagen Inc. Appoints Chas McKhann to Board of Directors Exhibit 99.1 Exagen Inc. Appoints Chas McKhann to Board of Directors Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July X, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions le |
|
| July 17, 2025 |
Amended & Restated Non-Employee Director Compensation Program Exhibit 10.1 EXAGEN INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Eligible Directors (as defined below) on the board of directors (the “Board”) of Exagen Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation describe |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 30, 2025 |
EXAGEN INC. 1261 LIBERTY WAY VISTA, CA 92081 EXAGEN INC. 1261 LIBERTY WAY VISTA, CA 92081 June 30, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: Exagen Inc. Registration Statement on Form S-3 File No. 333-288199 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C p |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par v |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 457( |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 As filed with the Securities and Exchange Commission on May 20, 2025 Registration No. |
|
| May 9, 2025 |
EX-99.1 Exhibit 99.1 Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares CARLSBAD, Calif., May 9, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-39049 Delaware 20-0434866 (State or other jurisdiction of incorporation) (IR |
|
| May 8, 2025 |
Exagen Inc. Prices Public Offering of Common Stock Exhibit 99.2 Exagen Inc. Prices Public Offering of Common Stock CARLSBAD, Calif., May 8, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share in the offering will be sold by Exage |
|
| May 8, 2025 |
3,350,000 Shares of Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-275632 PROSPECTUS SUPPLEMENT (To Prospectus dated November 29, 2023) 3,350,000 Shares of Common Stock We are offering 3,350,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “‘XGN.” On May 7, 2025, the last reported sale price of our common stock on The Nasdaq Global |
|
| May 8, 2025 |
Underwriting Agreement, dated May 8, 2025, by and between Exagen Inc. and Canaccord Genuity LLC. Exhibit 1.1 Exagen Inc. 3,350,000 Shares Common Stock Underwriting Agreement May 8, 2025 Canaccord Genuity LLC As Representative of the several Underwriters 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 Ladies and Gentlemen: Exagen Inc., a Delaware corporation (the “Company”), confirms its agreement with Canaccord Genuity LLC (“Canaccord”) and each of the other Underwriters named in |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 8, 2025 |
Exagen Inc. Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Exagen Inc. Announces Proposed Public Offering of Common Stock CARLSBAD, Calif., May 7, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day optio |
|
| May 7, 2025 |
SUBJECT TO COMPLETION, DATED MAY 7, 2025. 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-275632 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 5, 2025 |
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume May 5, 2025 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. Three Months Ended March 31, 2025 2024 (in thousands, except ASP data) Revenue $ 15, |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as speci |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 30, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 28, 2025 |
Exhibit 10.1 [***]: THE IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THE AGREEMENT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CREDIT AGREEMENT AND GUARANTY dated as of APRIL 25, 2025 among EXAGEN INC., as the Borrower, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, as Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as Lenders, AND PER |
|
| April 28, 2025 |
Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION |
|
| April 28, 2025 |
Exhibit 99.1 Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors $25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital April 28, 2025 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreemen |
|
| April 28, 2025 |
Exhibit 10.2 SECURITY AGREEMENT Dated as of April 25, 2025 among EXAGEN INC., as Grantor, THE OTHER GRANTORS FROM TIME TO TIME PARTY HERETO and PERCEPTIVE CREDIT HOLDINGS IV, LP, as Administrative Agent TABLE OF CONTENTS SECTION HEADING PAGE SECTION 1. DEFINITIONS, ETC. 1 Section 1.01. Certain Uniform Commercial Code Terms 1 Section 1.02. Additional Definitions 1 Section 1.03. Other Defined |
|
| March 11, 2025 |
Insider Trading Policies and Procedures. EXAGEN INC. AMENDED AND RESTATED INSIDER TRADING COMPLIANCE POLICY This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: •Section I provides an overview; •Section II sets forth the policies of Exagen Inc. prohibiting insider trading; •Section III explains insider trading; •Section IV consists of procedures that have been put in place by Exagen Inc. to prevent insider t |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Ex |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 11, 2025 |
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss, net loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune test |
|
| January 13, 2025 |
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn January 12, 2025 Carlsbad, |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 12, 2024 |
XGN / Exagen Inc. / Hunt Holdings Limited Partnership - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 eh24056697513ga3-xgn.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 12, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 12, 2024 |
Exagen Inc. Reports Third Quarter 2024 Results Expanded AVISE® CTD trailing twelve-month average selling price Reduced Adjusted EBITDA loss for first three quarters of 2024 Revenue in line with expectations, excluding one-time adjustments November 12, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the qua |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as s |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 5, 2024 |
Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan. Exhibit 10.3 EXAGEN INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN Effective as of April 25, 2022 Exagen Inc., a Delaware corporation (the “Company”), has adopted this Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions |
|
| August 5, 2024 |
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance August 5, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: •Recognized record total revenue of $15.1 million in the second quarter of 2024. •Delivered gross margin o |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specif |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 2, 2024 |
Employment Agreement, dated as of September 1, 2024, by and between the Company and Jeffrey Black. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of September 1, 2024 (the “Effective Date”) by and between Exagen Inc. (the “Company”), a Delaware corporation, and Jeff Black (“Executive”). References below to the “Company” shall include its subsidiaries and affiliates when applicable. 1.Roles and Duties. Subject to the terms and conditions of this Ag |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Comm |
|
| August 2, 2024 |
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer Exhibit 99.1 Exagen Appoints Jeffrey G. Black as New Chief Financial Officer August 1, 2024 CARLSBAD, Calif., - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will ac |
|
| June 11, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as speci |
|
| May 13, 2024 |
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year May 13, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: •Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first q |
|
| May 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 457( |
|
| May 13, 2024 |
As filed with the Securities and Exchange Commission on May 13, 2024 As filed with the Securities and Exchange Commission on May 13, 2024 Registration No. |
|
| May 13, 2024 |
Exhibit 10.1 Execution Version FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into effective as of April 12, 2024, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, “Innovatus”), as collateral agent (in such capacity, together with its |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
Exagen Inc. Announces Changes to the Board of Directors Exhibit 99.1 Exagen Inc. Announces Changes to the Board of Directors San Diego, Calif., April 25, 2024 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spe |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Ex |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 18, 2024 |
Exhibit 4.8 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description summarizes some of the terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of i |
|
| March 18, 2024 |
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results March 18, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: •Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million fo |
|
| February 14, 2024 |
XGN / Exagen Inc. / RTW INVESTMENTS, LP - EXAGEN INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2024 |
XGN / Exagen Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2024 |
XGN / Exagen Inc. / TULLIS DICKERSON CAPITAL FOCUS III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d748599dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Exagen, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement) Check the appr |
|
| February 13, 2024 |
XGN / Exagen Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 xgn13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 2, 2024 |
XGN / Exagen Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G/A 1 xgna420224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Exagen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068x103 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box t |
|
| January 22, 2024 |
XGN / Exagen Inc. / NMSIC Co-Investment Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 ef20019398sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| January 8, 2024 |
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance January 7, 2024 Carlsbad, CA – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. Select Preliminary Unaudited Financial Resul |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 11, 2023 |
Consulting Agreement, dated as of December 6, 2023, by and between the Company and Mark Hazeltine. Exhibit 10.1 ***THIS OFFER MUST BE ACCEPTED BY DECEMBER 10, 2023*** PROFESSIONAL SERVICES AGREEMENT This Professional Services Agreement (the “Agreement”) is effective as of December 6, 2023, by and between Exagen Inc. (the “Company”), a Delaware corporation with offices at 1261 Liberty Way, Vista, CA 92081, and John Mark Hazeltine (the “Consultant”) with a business location at . 1. Consulting Ser |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 29, 2023 |
PROSPECTUS SUPPLEMENT (To Prospectus Dated November 29, 2023) COMMON STOCK Filed pursuant to Rule 424(b)(5) Registration No. 333-275632 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 29, 2023) $10,223,534 COMMON STOCK On September 15, 2022, we entered into a sales agreement, as amended on November 17, 2023, or the sales agreement, with Cowen and Company LLC, or TD Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanyin |
|
| November 28, 2023 |
Exagen Inc. 1261 Liberty Way Vista, California 92081 Exagen Inc. 1261 Liberty Way Vista, California 92081 November 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Exagen Inc. Registration Statement on Form S-3 File No. 333-275632 (the "Registration Statement") Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulat |
|
| November 27, 2023 |
As filed with the Securities and Exchange Commission on November 27, 2023 As filed with the Securities and Exchange Commission on November 27, 2023 Registration Statement No. |
|
| November 27, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3/A (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carryforward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| November 20, 2023 |
Up to $10,822,402 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-250015 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated September 15, 2022 and Prospectus Dated November 19, 2020) Up to $10,822,402 Common Stock This prospectus supplement amends and supplements the information in our prospectus supplement dated September 15, 2022 (the “Initial Prospectus Supplement”). This prospectus supplement should be |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration Statement No. |
|
| November 17, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carryforward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| November 17, 2023 |
Exhibit 1.1 |
|
| November 17, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 13, 2023 |
Exagen Inc. Reports Strong Third Quarter 2023 Results Exagen Inc. Reports Strong Third Quarter 2023 Results November 13, 2023 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. •Recognized total revenue of $13.4 million for the third quarter of 2023. •Delivered gross margin of 57.4% for the third quarter of 2023. •AVISE® CTD trailing twe |
|
| November 13, 2023 |
Exhibit 10.1 |
|
| November 13, 2023 |
Exhibit 10.2 EXAGEN INC. CLAWBACK POLICY I.Introduction The Compensation Committee of the Board of Directors (the “Committee”) of Exagen Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Com |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as s |
|
| November 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specif |
|
| August 7, 2023 |
Exagen Inc. Reports Strong Second Quarter 2023 Results Exagen Inc. Reports Strong Second Quarter 2023 Results August 7, 2023 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. Second Quarter Highlights: •Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022. •Recognized total revenue o |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 24, 2023 |
Exagen Inc. Appoints Paul Kim to Board of Directors Exhibit 99.1 Exagen Inc. Appoints Paul Kim to Board of Directors July 24, 2023 at 9:00 AM EDT SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 18, 2023 |
EX-FILING FEES 2 exhibit107-formsx8calculat.htm EX-107 (FILING FEES) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 18, 2023 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No. |
|
| May 15, 2023 |
Exagen Inc. Reports First Quarter 2023 Results Record Physician Demand for AVISE® CTD Exagen Inc. Reports First Quarter 2023 Results Record Physician Demand for AVISE® CTD May 15, 2023 SAN DIEGO – Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023. First Quarter Highlights: •Delivered a record 37,312 AVISE® CTD tests in the first quarter, a 21% increase over the first quarter |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as speci |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into effective as of April 28, 2023, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, “Innovatus”), as collateral agent (in such capacity, together with its successors and assi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
DEF 14A 1 a2023def14aproxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 20, 2023 |
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results Record AVISE® CTD Volume in 2022 Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results Record AVISE® CTD Volume in 2022 March 20, 2023 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: •Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 t |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Ex |
|
| February 14, 2023 |
XGN / Exagen Inc / RTW INVESTMENTS, LP - EXAGEN INC. Passive Investment SC 13G/A 1 p23-0496sc13ga.htm EXAGEN INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate bo |
|
| February 13, 2023 |
XGN / Exagen Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2023 |
XGN / Exagen Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 7, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen, Inc. (Name of Issuer) Common shares, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 6, 2023 |
XGN / Exagen Inc / BANK OF MONTREAL /CAN/ - BANK OF MONTREAL Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exagen Inc (Name of Issuer) Common (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 2, 2023 |
XGN / Exagen Inc / NMSIC Co-Investment Fund, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 23, 2023 |
XGN / Exagen Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Exagen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068x103 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 23, 2023 |
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors Exhibit 99.1 Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors January 23, 2023 San Diego, CA Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 23, 2023 |
Amendment to Amended and Restated Bylaws, dated January 19, 2023 Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF EXAGEN INC. Pursuant to Article X of the Amended and Restated Bylaws (the “Bylaws”) of Exagen Inc. (the “Corporation”), the Bylaws are hereby amended as follows: Section 3.3 of the Bylaws is hereby amended and restated in its entirety, as follows: “3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS. Except as provided in Section |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 9, 2023 |
Exhibit 99.1 |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 5, 2022 |
Exhibit 10.1 Independent Contractor Agreement This Independent Contractor Agreement (?Agreement?) is made and entered into as of December 5, 2022 by and between Exagen Inc., a Delaware corporation (?Company?), and Debra Zack, MD, Ph.D., an individual (?Contractor?), with respect to the following facts: A. Company would like to engage Contractor as an independent contractor to assist with transitio |
|
| November 23, 2022 |
XGN / Exagen Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as s |
|
| November 14, 2022 |
Exagen Inc. Reports Third Quarter 2022 Results Medicare Reimbursement Returns Exagen Inc. Reports Third Quarter 2022 Results Medicare Reimbursement Returns November 14, 2022 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: ?Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE? CTD test, including |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39049 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| October 20, 2022 |
Employment Agreement, dated as of October 16, 2022, by and between the Company and John Aballi EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is effective as of October 16, 2022 (the ?Effective Date?) by and between Exagen, Inc. |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 20, 2022 |
Severance Agreement, dated as of October 14, 2022, by and between the Company and Ron Rocca SEVERANCE AGREEMENT October 14, 2022 BY EMAIL Fortunato Ron Rocca Dear Ron: The purpose of this Severance Agreement (the ?Severance Agreement?) is to set forth the terms of your separation from Exagen, Inc. |
|
| October 20, 2022 |
Exagen Announces Appointment of John Aballi as CEO Exagen Announces Appointment of John Aballi as CEO October 17, 2022 at 9:00 AM EDT SAN DIEGO, Oct. |
|
| September 15, 2022 |
EX-1.1 2 ex11-xgnxsalesagreement.htm EX-1.1 Exhibit 1.1 EXAGEN INC. $50,000,000 SALES AGREEMENT September 15, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Exagen Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time dur |
|
| September 15, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-250015 PROSPECTUS SUPPLEMENT (To Prospectus dated November 19, 2020) $50,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sale |
|
| September 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 4, 2022 |
Exagen Inc. Reports Second Quarter 2022 Results Records in AVISE? CTD Volume, Ordering Healthcare Providers and Adopters August 4, 2022 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights: ?Recognized total revenue of $9.0 million for the second quarter of 2022. Ou |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specif |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 11, 2022 |
Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan. Exhibit 10.1 EXAGEN INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN Effective as of April 25, 2022 Exagen Inc., a Delaware corporation (the ?Company?), has adopted this Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan, including the attached Exhibits (the ?Plan?), for the benefit of Participants (as defined below) on the terms and conditions |
|
| May 11, 2022 |
Exagen Inc. Reports First Quarter 2022 Results Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE? CTD Monthly Volume in March May 11, 2022 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights: ?Generated total revenue of $10.4 mill |
|
| May 11, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Exagen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 457( |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as speci |
|
| May 11, 2022 |
As filed with the Securities and Exchange Commission on May 11, 2022 As filed with the Securities and Exchange Commission on May 11, 2022 Registration No. |
|
| April 28, 2022 |
Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan Exhibit 10.1 EXAGEN INC. AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN Effective as of April 25, 2022 Exagen Inc., a Delaware corporation (the ?Company?), has adopted this Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan, including the attached Exhibits (the ?Plan?), for the benefit of Participants (as defined below) on the terms and conditions |
|
| April 28, 2022 |
DEF 14A 1 a2022def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Ex |
|
| March 22, 2022 |
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers March 22, 2022 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended D |
|
| March 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 15, 2022 |
XGN / Exagen Inc / BANK OF MONTREAL /CAN/ - BANK OF MONTREAL Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Exagen Inc (Name of Issuer) Common (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) |
|
| February 14, 2022 |
XGN / Exagen Inc / RTW INVESTMENTS, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen, Inc. (Name of Issuer) Common shares, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 14, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| February 14, 2022 |
XGN / Exagen Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 10, 2022 |
XGN / Exagen Inc / NMSIC Co-Investment Fund, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 8, 2022 |
XGN / Exagen Inc / Hunt Holdings Limited Partnership - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 20, 2022 |
XGN / Exagen Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G/A 1 xgna212022.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exagen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068x103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box t |
|
| January 19, 2022 |
XGN / Exagen Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exagen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068x103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 10, 2022 |
EXAGEN CONFIDENTIAL1 Rheumatoid Arthritis Drug Response This presentation contains forward-looking statements. |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 27, 2021 |
XGN / Exagen Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| December 17, 2021 |
XGN / Exagen Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G 1 xgn121721.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Exagen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068x103 (CUSIP Number) September 10, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 10, 2021 |
Exhibit 10.3 FIFTH ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET DATED JANUARY 13, 2012 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITES B & C, CALIFORNIA. Lessor and Lessee mutually agree to amend the lease as follows: Parties (1.1): Lessee has changed their name and shall here for be refer |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as s |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 10, 2021 |
Exhibit 10.6 September 28, 2021 Mr. Mike Walther Prometheus Laboratories Inc. 9410 Carroll Park Dr., Suite A San Diego, CA 92121 Dear Mr. Walther, This Letter Agreement represents the agreement between Prometheus Laboratories Inc. (?Prometheus?) and Exagen Inc. (?Exagen?) regarding the sale of certain intellectual property of Prometheus relating to methotrexate metabolites and pharmacogenetics as |
|
| November 10, 2021 |
Exhibit 10.1 SUBLEASE AGREEMENT This SUBLEASE AGREEMENT (?Sublease?) is entered into as of the date of last signature below, by and between PLUM HEALTHCARE GROUP, LLC, a California limited liability company (?Sublandlord?) whose address is 2175 Salk Avenue, Carlsbad, CA 92008 and EXAGEN INC., a Delaware corporation (?Subtenant?) whose address is 1261 Liberty Way, Vista, CA 92081. RECITALS A. BROOK |
|
| November 10, 2021 |
Exhibit 10.4 FIRST ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET DATED FEBRUARY 27, 2020 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITE A, CALIFORNIA. Lessor and Lessee mutually agree to amend the lease as follows: Parties (1.1): Lessee has changed their name and shall be referred to as Exa |
|
| November 10, 2021 |
Exhibit 10.5 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Agreement?) is entered into effective as of November 1, 2021, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, ?Innovatus?), as collateral agent (in such capacity, together with its successors and |
|
| November 10, 2021 |
Exhibit 10.2 SECOND AMENDMENT OF LEASE This Second Amendment of Lease is made on October 11, 2021, between Liberty Vista, a California limited partnership, ("Lessor"), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., ("Lessee"), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows: 1.Recitals. This Second Amendment of Lease is made with r |
|
| November 10, 2021 |
Exagen Inc. Reports Third Quarter 2021 Results Quarterly Records: Ordering Healthcare Providers and Adopters November 10, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights: ?Generated total revenue of $12.3 million for the third quarter of 2021, a 14% in |
|
| October 25, 2021 |
Exagen Inc. Announces $27.2 Million Debt Refinancing Exhibit 99.1 Exagen Inc. Announces $27.2 Million Debt Refinancing October 25, 2021 SAN DIEGO, CA ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC (?Innovatus?). The amended agreement provides a $27.2 million, 5 |
|
| October 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2021 |
Exagen Inc. Reports Second Quarter 2021 Results Quarterly Records: Total Revenue, AVISE? CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters August 9, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights: ?Generated record total revenue of $12.8 |
|
| August 9, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED. AMENDMENT #4 TO CO-PROMOTION AGREEMENT As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, |
|
| August 9, 2021 |
Exhibit 4.5 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK EXAGEN INC. Warrant Shares: Initial Exercise Date: , 2021 Issue Date: , 2021 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specif |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 30, 2021 |
Exagen Appoints Ana Hooker to Board of Directors Exagen Appoints Ana Hooker to Board of Directors July 30, 2021 SAN DIEGO ? Exagen Inc. |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 11, 2021 |
Exagen Inc. Reports First Quarter 2021 Results Quarterly Records: AVISE? CTD Volumes, Ordering Healthcare Providers and Adopters May 11, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2021. First Quarter Highlights: ?Generated total revenue of $10.6 million for the quarter ended March |
|
| May 11, 2021 |
As filed with the Securities and Exchange Commission on May 11, 2021 Registration No. |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as speci |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-3 |
|
| March 23, 2021 |
Exhibit 1.1 EXAGEN INC. (a Delaware corporation) 3,700,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 22, 2021 3,700,000 Shares of Common Stock UNDERWRITING AGREEMENT March 22, 2021 Cowen and Company, LLC William Blair & Company, L.L.C. Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o |
|
| March 23, 2021 |
Exagen Inc. Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Exagen Inc. Announces Pricing of Public Offering of Common Stock March 22, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to be sold in the offering are to be sold by Exag |
|
| March 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 23, 2021 |
Exagen Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Exagen Inc. Announces Proposed Public Offering of Common Stock March 22, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Exagen intends to grant the underwriters a 30-day o |
|
| March 23, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250015 PROSPECTUS SUPPLEMENT (To Prospectus dated November 19, 2020) 3,700,000 Shares Common Stock We are offering 3,700,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?XGN.? On March 22, 2021, the last reported sales price of our common stock on the Nasdaq Global Market |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 22, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250015 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| March 22, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF EXAGEN INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATION |
|
| March 16, 2021 |
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results Quarterly Records: Revenue, Gross Margin, AVISE? CTD Volumes and Adopters March 16, 2021 SAN DIEGO ? Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights: ?Generated total revenue of $42.0 million fo |
|
| March 16, 2021 |
Exhibit 10.34 FIRST AMENDMENT OF LEASE This First Amendment of Lease is made on December 30, 2020, between Liberty Vista, a California limited partnership, ("Lessor"), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., ("Lessee"), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows: 1.Recitals. This First Amendment of Lease is made with re |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 16, 2021 |
Executive Change in Control Severance Plan. Exhibit 10.46 EXAGEN INC. EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN Exagen Inc., a Delaware corporation (the ?Company?), has adopted this Exagen Inc. Executive Change in Control Severance Plan, including the attached Exhibits (the ?Plan?), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as set forth herein, is intended to provide severa |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Ex |
|
| March 16, 2021 |
Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan. Exhibit 10.5 EXAGEN INC. 2019 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Exagen Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Exagen Inc. 2019 Incentive Award Plan (as |
|
| March 16, 2021 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED. AMENDMENT #3 TO CO-PROMOTION AGREEMENT As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, |
|
| February 24, 2021 |
SC 13D United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Exagen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30068X103 (CUSIP Number) H.I. |
|
| February 24, 2021 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Exagen, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2021 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 11, 2021 |
Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results Record Testing Revenue, Adopters and AVISE CTD® Volumes January 10, 2021 - San Diego, CA Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported preliminary, unaudited financial results for the quarter ended December 31, 2020. Testing r |
|
| December 28, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Comm |
|
| November 17, 2020 |
Exagen Inc. 1261 Liberty Way Vista, California 92081 November 17, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Exagen Inc. Registration Statement on Form S-3 File No. 333-250015 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as a |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commi |
|
| November 10, 2020 |
Exagen Inc. Reports Third Quarter 2020 Results Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing November 10, 2020 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended September 30, 2020. Third Quarter High |
|
| November 10, 2020 |
Exhibit 10.1 EXAGEN INC. 1261 Liberty Way Vista, CA 92081 October 7, 2020 Innovatus Life Sciences Lending Fund I, LP 777 Third Avenue, 25th Floor New York, NY 10017 Attentionn: Claes Ekstrom Re: New Management Plan Ladies and Gentlemen: We refer to that certain Loan and Security Agreement, dated as of September 7, 2017 (as the same may from time to time be amended, modified, supplemented or restat |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as |
|
| November 10, 2020 |
As filed with the Securities and Exchange Commission on November 10, 2020 As filed with the Securities and Exchange Commission on November 10, 2020 Registration No. |
|
| November 10, 2020 |
Exhibit 4.10 EXAGEN INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishment o |
|
| September 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Com |
|
| September 18, 2020 |
XGN / Exagen Inc. / NMSIC Co-Investment Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exagen Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30068X103 (CUSIP Number) September 1, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| July 28, 2020 |
AMENDMENT #2 TO CO-PROMOTION AGREEMENT This Amendment #2 ("Amendment") is signed as of the signature date(s) below and made effective as of 18 June, 2020 ("Effective Date") by and between Janssen Biotech, Inc. |
|
| July 28, 2020 |
Exagen Inc. Reports Second Quarter 2020 Results Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63% July 28, 2020 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended June 30, 2020. Second Quarter Highlights: •Generated t |
|
| July 28, 2020 |
AMENDMENT #1 TO CO-PROMOTION AGREEMENT This Amendment #1 ("Amendment") is signed as of the signature date(s) below and made effective as of January 1, 2019 ("Effective Date") by and between Janssen Biotech, Inc. |
|
| July 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as spec |
|
| June 29, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| June 29, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| June 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as s |
|
| May 11, 2020 |
Exagen Inc. Reports First Quarter 2020 Results AVISE® Testing Volumes Increase with Retention Rate of 99% May 11, 2020 SAN DIEGO – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended March 31, 2020. First Quarter Highlights: •Generated total revenue of $9.6 mi |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 25, 2020 |
Exagen Inc. Reports Fourth Quarter and Full Year 2019 Results AVISE® Testing Revenue Drives 24% Revenue Growth March 25, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today reported |
|
| March 25, 2020 |
XGN / Exagen Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. |
|
| March 25, 2020 |
Exhibit 10.32 EXTENSION OF LEASE This Extension of Lease is made on February 25, 2020, between Liberty Vista, a California limited partnership ("Lessor"), whose address is 1000 Pioneer Way, El Cajon. CA 92020, and Exagen Diagnostics. lnc., ("Lessee"), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows: 1.Recitals. This Extension of Lease is made with reference to the foll |
|
| March 25, 2020 |
Exhibit 10.28 THIRD ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE – NET DATED JANUARY 13, 2012 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC. AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITE B AND C, CALIFORNIA. Lessor and Lessee mutually agree to amend the lease as follows: Paragraph 1.3 (Term): The Lease Term will be extended to the new Expira |
|
| March 25, 2020 |
Exhibit 10.31 FIRST ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE – NET DATED AUGUST 15, 2014 BY AND BETWEEN GEIGER COURT, LLC, AS LESSOR AND EXAGEN DIAGNOSTICS, INC. AS LESSEE, FOR THE PREMISES LOCATED AT 1221 LIBERTY WAY, VISTA, CALIFORNIA. Lessor and Lessee mutually agree to amend the lease as follows: Paragraph 1.3 (Term): The Lease Term will be extended to the new Expiration |
|
| March 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2020 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 001-39049 20-0434866 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 25, 2020 |
Exhibit 10.36 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of November 19, 2019, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, “Innovatus”), as collateral agent (in such capacity, together with its successors and assigns in |
|
| March 25, 2020 |
Offer Letter dated February 21, 2020, by and between Debra Zack, MD Ph.D. and the Company. Exhibit 10.41 EXAGEN INC. February 21, 2020 Debra Zack, MD Ph.D. Dear Dr. Zack, I am pleased to confirm our offer for you to join Exagen Inc. as Chief Medical Officer with a start date of 3/24/2020. This offer is contingent upon the successful completion of a pre-employment background check and proof of work eligibility. This is an exempt position and will report to Ron Rocca. We are offering you |
|
| March 25, 2020 |
Exhibit 10.33 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE-NET 1. Basic Provisions ("Basic Provisions"). 1.1 Parties. This Lease ("Lease"), dated for reference purposes only February 27, 2020 , is made by and between RGS Properties ("Lessor") and Exagen Diagnostics, Inc ("Lessee"), (collectively the "Parties", or individually a "Party"). 1.2(a) Premises: That certain real property, including |
